Current status of the anticoagulant hirudin: its biotechnological production and clinical practice
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sohn, J.H. | - |
dc.contributor.author | Kang, H.A. | - |
dc.contributor.author | Rao, K.J. | - |
dc.contributor.author | Kim, C.H. | - |
dc.contributor.author | Choi, E.S. | - |
dc.contributor.author | Chung, B.H. | - |
dc.contributor.author | Rhee, S.K. | - |
dc.date.accessioned | 2022-04-29T07:40:12Z | - |
dc.date.available | 2022-04-29T07:40:12Z | - |
dc.date.issued | 2001-12 | - |
dc.identifier.issn | 0175-7598 | - |
dc.identifier.issn | 1432-0614 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/56997 | - |
dc.description.abstract | Hirudin is a potent thrombin inhibitor originally derived from the medicinal leech, Hirudo medicinalis. Owing to its high affinity and specificity for thrombin, hirudin has been intensively investigated for research and therapeutic purposes. The investigation of hirudin has contributed greatly to the understanding of the mode of action of thrombin and the clotting system. Hirudin and several hirudin analogues have also been demonstrated to have several advantages as a highly specific anticoagulant over the most widely used drug, heparin. Due to the great demand for hirudin in physicochemical and clinical studies, various recombinant systems have been developed, using bacteria, yeasts, and higher eukaryotes, to obtain the biologically active hirudin in significant quantities. After 10 years of clinical applications, two recombinant hirudins and a hirudin analogue have gained marketing approval from the United States Food and Drug Administration, for several applications. Clinical trials are currently ongoing for other treatments for thrombotic disease. As a consequence, it is conceivable that hirudin may expand its therapeutic utility over heparin in the near future. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPRINGER | - |
dc.title | Current status of the anticoagulant hirudin: its biotechnological production and clinical practice | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s00253-001-0856-9 | - |
dc.identifier.bibliographicCitation | APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, v.57, no.5-6, pp 606 - 613 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000172959700003 | - |
dc.identifier.scopusid | 2-s2.0-0035660816 | - |
dc.citation.endPage | 613 | - |
dc.citation.number | 5-6 | - |
dc.citation.startPage | 606 | - |
dc.citation.title | APPLIED MICROBIOLOGY AND BIOTECHNOLOGY | - |
dc.citation.volume | 57 | - |
dc.type.docType | Review | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Heparin | - |
dc.subject.keywordAuthor | Marketing | - |
dc.subject.keywordAuthor | Thrombin | - |
dc.subject.keywordAuthor | States Food | - |
dc.subject.keywordAuthor | Great Demand | - |
dc.subject.keywordPlus | HEPARIN-INDUCED THROMBOCYTOPENIA | - |
dc.subject.keywordPlus | THROMBIN-SPECIFIC INHIBITOR | - |
dc.subject.keywordPlus | MOLECULAR-WEIGHT HEPARIN | - |
dc.subject.keywordPlus | AMINO-ACID-SEQUENCE | - |
dc.subject.keywordPlus | RECOMBINANT HIRUDIN | - |
dc.subject.keywordPlus | SACCHAROMYCES-CEREVISIAE | - |
dc.subject.keywordPlus | BIOCHEMICAL-CHARACTERIZATION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | SECRETION | - |
dc.subject.keywordPlus | LEECH | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.